1. Clinical-Risk Factors that Influence an Optimal Hypomethylating Agents Treatment in Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia. (April 2017) Authors: Iastrebner, M.; Lazzarino, C.; Nucifora, E.; Penchasky, D.; Fernandez, I.; Gusmao Moreno, B.G.M.; Rivas, M.M.; Espinosa, D.; Abello Polo, V.; Boada, M.; Enrico, A.; Araujo Schuster, S.; Agra, M.; Sarmiento, M.; Flores, G.; Alfonso, G.; Crisp, R.; Gusmao Moreno, B.; Consortium, I. Journal: Leukemia research Issue: Volume 55(2017)Supplement 1 Page Start: S64 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Lower-Risk Patients that Required Hypomethylating Agents. A Multicentric Experience from Latin America. (April 2017) Authors: Iastrebner, M.; Belli, C.; Lazzarino, C.; Fantl, D.; Pintos, N.; Bengio, R.; Prates, M.V.; Rosenhain, M.; Pose, J.; Celebrin, L.; Moro, D.; Garcia Rivello, H.; Grille, S.; Flores, G.; Rivas, M.M.; Enrico, A.; Abello Polo, V.; Araujo Schuster, S.; Arbelbide, J.; Consortium, I. Journal: Leukemia research Issue: Volume 55(2017)Supplement 1 Page Start: S64 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗